Skip to main content
< Back to news
Joaquín Querol, CEO and cofounder of Endor Technologies. Image / PCB
 17.02.2026

Endor Technologies, recognized in the Deloitte Technology Fast 50 as one of the fastest‑growing tech companies in Spain

Endor Technologies, a company specialized in developing medical solutions based on biotechnology applied to oncology and dermocosmetics, has been recognized in the Deloitte Technology Fast 50 Programme as one of the fastest‑growing technology companies in Spain. The company ranks 20th on the list, after recording a cumulative revenue growth of 469% over the past four years.

The Deloitte Technology Fast 50 Spain program identifies and gives visibility to the most scalable technology companies in the national entrepreneurial ecosystem, based on the percentage growth of their revenue over the last four-year period.

A hybrid model that funds science

Founded in Barcelona in 2007 as a scientific spin‑off of the Catalan Institute of Nanotechnology, Endor Technologies was born with a clear purpose: to translate advances in oncological research into real solutions for patients.

Since its inception, Endor Technologies has been driven by a strongly medical vocation: bringing advances in cancer research to real patient solutions. From the beginning, the company has developed a disruptive theory of cancer based on tumor growth dynamics, validated in a preclinical phase between 2010 and 2015 and currently in clinical reactivation.

One of Endor’s distinctive traits has been its growth model. In 2018, it launched a dermocosmetics line based on nanotechnology with the aim of funding its research without relying on external investment. This division, conceived as a tool for technology transfer and self‑financing, closed 2025 with nearly €6 million in revenue, enabling sustained reinvestment in oncology R&D and consolidating organic, long‑term growth.

Joaquín Querol, CEO and co‑founder of Endor Technologies, states: “This recognition validates many years of sustained work, commitment to rigorous science, and organic growth. At Endor, we have always been clear that we wanted to maintain our independence in order to research freely and in depth. We will continue reinvesting every advance in research, because our purpose is to transform cancer treatment with innovative and sustainable solutions.”

2025: a year of strategic consolidation

During the last financial year, Endor has taken key steps in its scientific and industrial roadmap. In June 2025, the company announced the launch of a pioneering Phase II clinical trial proposing a radically different approach in oncology: confining tumors by creating a physical barrier that limits their expansion, rather than focusing exclusively on cell destruction. The study, the only one of its kind worldwide, is supported by the Fundació Món Clínic Barcelona and coordinated by the Barcelona Clinical Coordinating Center (BCCC), with participation from a network of hospitals across Spain.

In parallel, the company has completed the adaptation of its new nanomedicine laboratory in Barcelona to comply with ISO 13485 standards for the manufacturing of medical devices. With this infrastructure, Endor becomes the only company in Spain capable of designing and internally producing active nanomolecules for medical devices, reinforcing a vertically integrated model that connects research, development, production, and clinical validation.

The company is also preparing to launch a new dermocosmetics collection representing the second generation of its proprietary technology. This evolution incorporates an optimized active‑delivery system capable of activating CD44 more effectively, reinforcing the brand’s scientific positioning and consolidating the cosmetics division as a strategic lever for growth and for financing oncology research.

With several international patents in oncology and nanomedicine, and €1.6 million in public funding from the CDTI, Endor has established itself as one of the unique cases in the Spanish biotech sector. The company has scaled by relying on its own revenue and building a model that combines business growth and scientific innovation with full strategic independence.